Analysts at BTIG Research started coverage on shares of Tempus AI (NASDAQ:TEM - Get Free Report) in a research note issued on Monday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $60.00 price target on the stock. BTIG Research's price objective would indicate a potential upside of 13.42% from the stock's current price.
TEM has been the subject of a number of other research reports. Wolfe Research downgraded Tempus AI from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Guggenheim reaffirmed a "buy" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Loop Capital reduced their target price on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating on the stock in a report on Tuesday, January 14th. Piper Sandler lowered their price target on shares of Tempus AI from $70.00 to $55.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $70.00 price objective on shares of Tempus AI in a research note on Thursday, April 10th. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $61.08.
Read Our Latest Analysis on TEM
Tempus AI Trading Down 1.1 %
NASDAQ TEM traded down $0.60 during trading hours on Monday, reaching $52.90. 8,979,690 shares of the stock traded hands, compared to its average volume of 5,649,576. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The stock has a 50 day simple moving average of $49.92 and a two-hundred day simple moving average of $50.44. Tempus AI has a 1 year low of $22.89 and a 1 year high of $91.45.
Insider Activity at Tempus AI
In other news, Director Wayne A.I. Frederick sold 3,000 shares of the firm's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $45.54, for a total value of $136,620.00. Following the completion of the sale, the director now directly owns 26,514 shares of the company's stock, valued at approximately $1,207,447.56. This trade represents a 10.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 79,118 shares of the business's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $53.86, for a total transaction of $4,261,295.48. Following the transaction, the chief executive officer now owns 5,692,669 shares in the company, valued at $306,607,152.34. This represents a 1.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,584,252 shares of company stock worth $272,870,580 in the last 90 days. Company insiders own 27.60% of the company's stock.
Institutional Trading of Tempus AI
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Stifel Financial Corp bought a new position in shares of Tempus AI in the 3rd quarter worth approximately $218,000. Geode Capital Management LLC increased its stake in shares of Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company's stock worth $7,537,000 after acquiring an additional 539 shares in the last quarter. Tidal Investments LLC purchased a new position in Tempus AI during the 3rd quarter valued at about $7,633,000. Franklin Resources Inc. boosted its stake in Tempus AI by 1.0% during the third quarter. Franklin Resources Inc. now owns 811,311 shares of the company's stock worth $45,920,000 after acquiring an additional 8,387 shares in the last quarter. Finally, Silverleafe Capital Partners LLC purchased a new stake in Tempus AI in the fourth quarter worth about $533,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Further Reading
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
